The oncolytic virus VT09X optimizes immune checkpoint therapy in low immunogenic melanoma.
Immunol Lett
; 241: 15-22, 2022 01.
Article
en En
| MEDLINE
| ID: mdl-34774916
ABSTRACT
Tumors with a low level of pre-existing immune cell infiltration respond poorly to immune checkpoint therapies. Oncolytic viruses optimize immunotherapies by modulating the tumor microenvironment and affecting multiple steps in the cancer-immunity cycle, making them an attractive agent for combination strategies. We engineered an HSV-1-based oncolytic virus and investigated its antitumor effects in combination with the marketed PD-1 antibody Keytruda (pembrolizumab) in hPD-1 knock-in mice bearing non-immunogenic B16-F10 melanoma. Our results showed enhanced CD8+ and CD4+ T cell infiltration, IFN-γ secretion and PD-L1 expression in tumors, subsequently leading to the prolonged overall survival of mice. Systemic changes in lymphocyte cell proportions were also observed in the peripheral blood. In summary, these findings provide evidence that oncolytic viruses can be engineered as a potential platform for combination therapies, especially to treat tumors that are poorly responsive to immune checkpoint therapy.
Palabras clave
Texto completo:
1
Banco de datos:
MEDLINE
Asunto principal:
Linfocitos Infiltrantes de Tumor
/
Linfocitopenia-T Idiopática CD4-Positiva
/
Herpesvirus Humano 1
/
Linfocitos T CD8-positivos
/
Virus Oncolíticos
/
Viroterapia Oncolítica
/
Anticuerpos Monoclonales Humanizados
/
Inhibidores de Puntos de Control Inmunológico
/
Herpes Simple
/
Melanoma
Tipo de estudio:
Prognostic_studies
Límite:
Animals
/
Humans
Idioma:
En
Revista:
Immunol Lett
Año:
2022
Tipo del documento:
Article
País de afiliación:
China